Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03768505




Registration number
NCT03768505
Ethics application status
Date submitted
4/12/2018
Date registered
7/12/2018
Date last updated
1/02/2024

Titles & IDs
Public title
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Scientific title
A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)
Secondary ID [1] 0 0
2018-002896-17
Secondary ID [2] 0 0
ME-401-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma (FL) 0 0
Non Hodgkin Lymphoma 0 0
Marginal Zone Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Zandelisib (ME-401)

Experimental: Zandelisib (ME-401) open label - Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).


Treatment: Drugs: Zandelisib (ME-401)
Zandelisib (ME-401) 60 mg
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) of ME-401 in Relapsed or Refractory FL or MZL
Timepoint [1] 0 0
3 years 9 months
Secondary outcome [1] 0 0
Duration of Response (DOR)
Timepoint [1] 0 0
3 years 9 months
Secondary outcome [2] 0 0
Complete Response (CR) Rate
Timepoint [2] 0 0
3 years 9 months
Secondary outcome [3] 0 0
Progression-free Survival (PFS)
Timepoint [3] 0 0
3 years 9 months
Secondary outcome [4] 0 0
Overall Survival
Timepoint [4] 0 0
2 years
Secondary outcome [5] 0 0
Overall Incidence of Treatment Emergent Adverse Events (TEAEs)
Timepoint [5] 0 0
3 years 9 months
Secondary outcome [6] 0 0
PK of ME-401
Timepoint [6] 0 0
3 years 9 months

Eligibility
Key inclusion criteria
- Histologically confirmed diagnosis as defined in the World Health Organization (WHO)
classification scheme

1. Follicular Lymphoma (FL) limited to Grade 1,2 or 3a or

2. Marginal Zone Lymphoma (MZL) including nodal, extranodal and splenic MZL

- Subjects that have had progression of disease or had no response to therapy after at
least 2 prior systemic therapies for FL or MZL

- Age = 18

- At least one bi-dimensionally measurable nodal lesion > 1.5 cm in its longest diameter
by computed tomography (CT) scan as defined by the Lugano Classification

- Adequate hematologic, renal and hepatic parameters at screening unless abnormal values
are due to FL per Investigator assessment

- QT-interval corrected according to Fridericia's formula (QTcF) = 450 milliseconds
(msec);

- Left ventricular ejection fraction (LVEF) = 45%
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Histologically confirmed FL Grade 3b transformation from FL to an aggressive lymphoma

- Known lymphomatous involvement of the central nervous system

- Uncontrolled clinically significant illness

- Ongoing or history of drug-induced pneumonitis

- History of clinically significant cardiovascular abnormalities

- History of clinically significant GI conditions

- Known history of, or active HIV infection

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/06/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/03/2023
Sample size
Target
Accrual to date
Final
169
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Peninsula and South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [2] 0 0
The Perth Blood Institute - West Perth
Recruitment hospital [3] 0 0
Liverpool Hospital - Sydney
Recruitment postcode(s) [1] 0 0
3199 - Frankston
Recruitment postcode(s) [2] 0 0
6005 - West Perth
Recruitment postcode(s) [3] 0 0
NSW2170 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Montana
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New Mexico
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Austria
State/province [20] 0 0
Linz
Country [21] 0 0
Austria
State/province [21] 0 0
Vienna
Country [22] 0 0
Belgium
State/province [22] 0 0
Brugge
Country [23] 0 0
Belgium
State/province [23] 0 0
Brussels
Country [24] 0 0
Belgium
State/province [24] 0 0
Edegem
Country [25] 0 0
France
State/province [25] 0 0
Bayonne
Country [26] 0 0
France
State/province [26] 0 0
La Roche-Sur-Yon Cedex 9
Country [27] 0 0
France
State/province [27] 0 0
Le Mans
Country [28] 0 0
France
State/province [28] 0 0
Mulhouse
Country [29] 0 0
France
State/province [29] 0 0
Poitiers
Country [30] 0 0
France
State/province [30] 0 0
Villejuif
Country [31] 0 0
Germany
State/province [31] 0 0
Rheinland-Pfalz
Country [32] 0 0
Germany
State/province [32] 0 0
Stolberg
Country [33] 0 0
Germany
State/province [33] 0 0
Halle
Country [34] 0 0
Germany
State/province [34] 0 0
Munich
Country [35] 0 0
Germany
State/province [35] 0 0
Münster
Country [36] 0 0
Germany
State/province [36] 0 0
Ulm
Country [37] 0 0
Italy
State/province [37] 0 0
Aviano
Country [38] 0 0
Italy
State/province [38] 0 0
Bologna
Country [39] 0 0
Italy
State/province [39] 0 0
Genova
Country [40] 0 0
Italy
State/province [40] 0 0
Meldola
Country [41] 0 0
Italy
State/province [41] 0 0
Napoli
Country [42] 0 0
Italy
State/province [42] 0 0
Ravenna
Country [43] 0 0
Italy
State/province [43] 0 0
Rimini
Country [44] 0 0
Italy
State/province [44] 0 0
Roma
Country [45] 0 0
Italy
State/province [45] 0 0
Rome
Country [46] 0 0
Italy
State/province [46] 0 0
Terni
Country [47] 0 0
Italy
State/province [47] 0 0
Venice
Country [48] 0 0
Korea, Republic of
State/province [48] 0 0
Busan
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Seoul
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Ulsan
Country [51] 0 0
New Zealand
State/province [51] 0 0
Auckland
Country [52] 0 0
New Zealand
State/province [52] 0 0
Dunedin
Country [53] 0 0
Poland
State/province [53] 0 0
Bydgoszcz
Country [54] 0 0
Poland
State/province [54] 0 0
Kraków
Country [55] 0 0
Poland
State/province [55] 0 0
Warszawa
Country [56] 0 0
Poland
State/province [56] 0 0
Wroclaw
Country [57] 0 0
Poland
State/province [57] 0 0
Lódz
Country [58] 0 0
Spain
State/province [58] 0 0
Tenerife
Country [59] 0 0
Spain
State/province [59] 0 0
Barcelona
Country [60] 0 0
Spain
State/province [60] 0 0
Madrid
Country [61] 0 0
Spain
State/province [61] 0 0
Pamplona
Country [62] 0 0
Spain
State/province [62] 0 0
Salamanca
Country [63] 0 0
Spain
State/province [63] 0 0
Sevilla
Country [64] 0 0
Spain
State/province [64] 0 0
Zaragoza
Country [65] 0 0
Switzerland
State/province [65] 0 0
Bellinzona
Country [66] 0 0
Taiwan
State/province [66] 0 0
Taichung
Country [67] 0 0
Taiwan
State/province [67] 0 0
Tainan City
Country [68] 0 0
Taiwan
State/province [68] 0 0
Tainan
Country [69] 0 0
Taiwan
State/province [69] 0 0
Taipei City
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Denbighire
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Sutton
Country [72] 0 0
United Kingdom
State/province [72] 0 0
UK
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Belfast
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Cornwell
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Liverpool
Country [76] 0 0
United Kingdom
State/province [76] 0 0
London
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Manchester
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Norwich
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Oxford
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
MEI Pharma, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is the study of the PI3Kd inhibitor Zandelisib (ME-401) in subjects with
relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2
prior lines of systemic therapy
Trial website
https://clinicaltrials.gov/ct2/show/NCT03768505
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03768505